Antion’s mirGE™ platform enables precise multiplex gene silencing with synthetic miRNAs, allowing independent modulation of up to 7 targets in a single step. Compatible with viral and non-viral delivery, it is designed for scalable, safe and effective ex vivo and in vivo therapies and R&D models.
Products, services, technology
Antion provides mirGE™ screening libraries, custom gene-engineering solutions, and pre-validated targets for allogeneic, hypoimmune, and enhanced cell therapies. The company also offers CAR-T programs for hematological and solid tumor indications.
Cooperation possibilities
Antion provides licensing, co-development, and custom engineering services based on its proprietary mirGE™ platform. With a fully operational lab and experienced scientific team, we partner with biotech, pharma, and technology companies to advance next-generation therapies.
- http://www.antionbio.com
- +41786215452
- Send an email
- Antonija Sakic
Some insights
Antion helps make advanced therapies more effective, safer, and easier to develop. Our technologies support the creation of innovative treatments that can improve outcomes for patients with life-threatening diseases.
We are proud of our ability to translate cutting-edge science into practical solutions, working with partners to accelerate the development of innovative therapies.
Our team combines expertise in gene engineering, cell therapy, translational research, and biotech operations. As we grow, we seek to strengthen business development, partnering, clinical development, and AI-enabled therapeutic design capabilities.
We welcome discussions with biotech and pharma partners, investors, technology providers, and translational research groups seeking innovative gene-engineering solutions, therapeutic assets, or strategic collaborations.
